Radiation and abemaciclib plus letrozole before breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be at least 1.5 cm and not feelable by touch, with no spread to lymph nodes.
- The cancer must be hormone receptor-positive (ER or PR positive) and HER2-negative.
- You must be postmenopausal, meaning you have not had a period for at least 12 months and blood tests confirm menopause.
- Your Oncotype DX recurrence score must be less than 25.
- You must be able to swallow pills and be healthy enough for surgery (lumpectomy or mastectomy).
- You cannot have had prior radiation to the chest or breast, or treatment with similar drugs (CDK4/6 inhibitors or aromatase inhibitors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
This trial tests a new combination of two oral medications—imlunestrant (a hormone therapy) and abemaciclib (a drug that blocks cancer growth)—given before surgery. The goal is to see if these drugs can shrink the tumor, using your tumor's growth rate (Ki67) after two weeks of treatment to guide further therapy.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.